PURPOSE: Investigator-initiated research involving investigational drugs and devices is key to improving health. However, this requires the investigator to serve as a "sponsor-investigator," which can be complex and overwhelming. The Investigational New Drug/Investigational Device Exemption (IND/IDE) Taskforce of the Clinical and Translational Science Award (CTSA) consortium carried out a survey to examine how academic health centers (AHCs) assist sponsor-investigators with regulatory responsibilities. METHOD: The 24 CTSA centers existing in 2008 were surveyed regarding regulatory oversight and support for sponsor-investigators. Responses were analyzed by descriptive statistics. The evaluation of survey responses yielded three models of institutional support/oversight. RESULTS: Nineteen centers and one affiliate responded. Eleven (55%) reported having an IND/IDE support office, increased from five (25%) prior to their CTSA award. The volume of investigator-initiated IND/IDE research was highly variable (measured by numbers of investigators, IND/IDE applications, and studies). Oversight, if done, was provided by either the IND/IDE office or elsewhere in the institution. Most IND/IDE offices assisted with IND/IDE submissions and preparation for external audits. Half reported advanced training for sponsor-investigators. Almost all reported a goal to increase IND/IDE research. Important issues include the need for robust training of investigator/staff, appropriate determination of IND-exempt research, and sufficient support for preparing IND/IDE applications. CONCLUSIONS: Investigator-initiated research involving IND/IDEs is essential, but complex. AHCs should examine how they support sponsor-investigators in meeting the complex requirements. A model of either expert consultation/support or full service will minimize risks to participants and institutions, and regulatory noncompliance.
PURPOSE: Investigator-initiated research involving investigational drugs and devices is key to improving health. However, this requires the investigator to serve as a "sponsor-investigator," which can be complex and overwhelming. The Investigational New Drug/Investigational Device Exemption (IND/IDE) Taskforce of the Clinical and Translational Science Award (CTSA) consortium carried out a survey to examine how academic health centers (AHCs) assist sponsor-investigators with regulatory responsibilities. METHOD: The 24 CTSA centers existing in 2008 were surveyed regarding regulatory oversight and support for sponsor-investigators. Responses were analyzed by descriptive statistics. The evaluation of survey responses yielded three models of institutional support/oversight. RESULTS: Nineteen centers and one affiliate responded. Eleven (55%) reported having an IND/IDE support office, increased from five (25%) prior to their CTSA award. The volume of investigator-initiated IND/IDE research was highly variable (measured by numbers of investigators, IND/IDE applications, and studies). Oversight, if done, was provided by either the IND/IDE office or elsewhere in the institution. Most IND/IDE offices assisted with IND/IDE submissions and preparation for external audits. Half reported advanced training for sponsor-investigators. Almost all reported a goal to increase IND/IDE research. Important issues include the need for robust training of investigator/staff, appropriate determination of IND-exempt research, and sufficient support for preparing IND/IDE applications. CONCLUSIONS: Investigator-initiated research involving IND/IDEs is essential, but complex. AHCs should examine how they support sponsor-investigators in meeting the complex requirements. A model of either expert consultation/support or full service will minimize risks to participants and institutions, and regulatory noncompliance.
Authors: Jana Shirey-Rice; Brandy Mapes; Melissa Basford; Anneliese Zufelt; Firas Wehbe; Paul Harris; Michael Alcorn; David Allen; Margaret Arnim; Susan Autry; Michael S Briggs; Andrea Carnegie; Deborah Chavis-Keeling; Carlos De La Pena; Doris Dworschak; Julie Earnest; Terri Grieb; Marilyn Guess; Nathaniel Hafer; Tesheia Johnson; Amanda Kasper; Janice Kopp; Timothy Lockie; Vincetta Lombardo; Leslie McHale; Andrea Minogue; Beth Nunnally; Deanna O'Quinn; Kelly Peck; Kieran Pemberton; Cheryl Perry; Ginny Petrie; Andria Pontello; Rachel Posner; Bushra Rehman; Deborah Roth; Paulette Sacksteder; Samantha Scahill; Lorri Schieri; Rosemary Simpson; Anne Skinner; Kim Toussant; Alicia Turner; Elaine Van der Put; June Wasser; Chris D Webb; Maija Williams; Lori Wiseman; Laurel Yasko; Jill Pulley Journal: Clin Transl Sci Date: 2014-01-23 Impact factor: 4.689
Authors: Joan E Adamo; Gerhard Bauer; Marlene Berro; Bruce K Burnett; Karen A Hartman; Lisa M Masiello; Diane Moorman-White; Eric P Rubinstein; Kathryn G Schuff Journal: Acad Med Date: 2012-03 Impact factor: 6.893
Authors: Erin K O'Reilly; M E Blair Holbein; Jelena P Berglund; Amanda B Parrish; Mary-Tara Roth; Bruce K Burnett Journal: Clin Invest Med Date: 2013-12-01 Impact factor: 0.825
Authors: M E Blair Holbein; Jelena Petrovic Berglund; Erin K O'Reilly; Karen Hartman; Lisa A Speicher; Joan E Adamo; Gerri O'Riordan; Jennifer Swanton Brown; Kathryn G Schuff Journal: J Investig Med Date: 2014-06 Impact factor: 2.895
Authors: Misty Gravelin; Jeanne Wright; M E Blair Holbein; Marlene Berro; Jennifer S Brown; George A Mashour; Kevin J Weatherwax Journal: J Clin Transl Sci Date: 2021-02-26